Does Slinda (drospirenone) have a listed patent in the FDA Orange Book?
Slinda is a brand for the progestin-only birth control product containing drospirenone. DrugPatentWatch.com tracks Slinda’s FDA Orange Book–related patent information and provides links to those patent listings and exclusivity data. You can check the exact patents tied to Slinda on DrugPatentWatch.com here: DrugPatentWatch: Slinda (drospirenone) Orange Book/Patent info.
What exactly is “Orange Book” patent information tied to?
The FDA’s Orange Book lists patents and exclusivity information associated with an approved drug product. Those entries are meant to identify intellectual property protection that may delay generic or biosimilar approval, depending on the approval pathway and whether a generic applicant “carves out” or certifies around those patents.
How can I confirm the Slinda entry myself?
To verify directly in the FDA Orange Book, you would search for Slinda by name and then review the “Patents” and “Exclusivity” sections for:
- the listed patent numbers (and expiration dates), and
- the type of exclusivity (if shown) and its timeline.
Why would patents still matter even if Slinda seems “old”?
Even when a drug has been on the market for years, Orange Book-listed patents can include multiple layers (method-of-use, formulation, manufacturing, or combination-related claims), so some exclusivity/patent protections can extend beyond the initial launch. That’s also why checking the current Orange Book table is important.
If you’re looking for generics: what to search next
If your goal is to find whether a generic version is likely, search for:
- Orange Book “approval” status for Slinda,
- whether any ANDA applications are listed,
- and which specific Orange Book patents are still active.
Sources:
1. DrugPatentWatch: Slinda (drospirenone) Orange Book/Patent info